JNJ

167.69

-0.36%↓

NVS

116.94

-0.3%↓

ABT

128.18

+0.74%↑

MDT

92.11

-0.35%↓

ELV.US

287.61

-2.37%↓

JNJ

167.69

-0.36%↓

NVS

116.94

-0.3%↓

ABT

128.18

+0.74%↑

MDT

92.11

-0.35%↓

ELV.US

287.61

-2.37%↓

JNJ

167.69

-0.36%↓

NVS

116.94

-0.3%↓

ABT

128.18

+0.74%↑

MDT

92.11

-0.35%↓

ELV.US

287.61

-2.37%↓

JNJ

167.69

-0.36%↓

NVS

116.94

-0.3%↓

ABT

128.18

+0.74%↑

MDT

92.11

-0.35%↓

ELV.US

287.61

-2.37%↓

JNJ

167.69

-0.36%↓

NVS

116.94

-0.3%↓

ABT

128.18

+0.74%↑

MDT

92.11

-0.35%↓

ELV.US

287.61

-2.37%↓

Search

Innoviva Inc

Deschisă

SectorSănătate

18.51 -0.86

Rezumat

Modificarea prețului

24h

Curent

Minim

18.37

Maxim

18.67

Indicatori cheie

By Trading Economics

Venit

-67M

-47M

Vânzări

-3.2M

89M

P/E

Medie Sector

51.694

38.156

Marjă de profit

-52.559

Angajați

127

EBITDA

-63M

-27M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+117.53% upside

Dividende

By Dow Jones

Următoarele câștiguri

5 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

48M

1.2B

Deschiderea anterioară

19.37

Închiderea anterioară

18.51

Sentimentul știrilor

By Acuity

46%

54%

148 / 375 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Strong Bullish Evidence

Innoviva Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

29 iul. 2025, 23:57 UTC

Achiziții, Fuziuni, Preluări

EQT: To Spend Y407.82B for Tender Offer

29 iul. 2025, 23:56 UTC

Achiziții, Fuziuni, Preluări

EQT: Tender Offer Price Is Y5,700 a Share

29 iul. 2025, 23:54 UTC

Achiziții, Fuziuni, Preluări

EQT To Start Tender Offer for Fujitec

29 iul. 2025, 23:50 UTC

Market Talk

Nikkei May Fall Amid Uncertainty Over Earnings, Domestic Politics -- Market Talk

29 iul. 2025, 23:36 UTC

Market Talk

Gold Steady Ahead of FOMC Decision -- Market Talk

29 iul. 2025, 22:57 UTC

Market Talk

Perseus May Step Up Capital Management at FY 2025 Result -- Market Talk

29 iul. 2025, 22:50 UTC

Market Talk

Mondelez Warns of Price Increases in North America -- Market Talk

29 iul. 2025, 22:44 UTC

Achiziții, Fuziuni, Preluări

St Barbara: Potential Divestment of Nova Scotia Ops to be Weighed in 1Q FY26

29 iul. 2025, 22:41 UTC

Achiziții, Fuziuni, Preluări

St Barbara FY25 All-in Sustaining Cost A$4,582/Oz

29 iul. 2025, 22:41 UTC

Achiziții, Fuziuni, Preluări

St Barbara 4Q All-in Sustaining Cost A$4,613/Oz

29 iul. 2025, 22:35 UTC

Câștiguri

IGO Maintains Nova Life of Mine Production Guidance

29 iul. 2025, 22:35 UTC

Câștiguri

IGO Expects FY 2026 Greenbushes Output of 1.50 Million-1.65 Million Tons

29 iul. 2025, 22:35 UTC

Câștiguri

IGO Expects FY 2026 Greenbushes Cash Costs of A$310-A$360/Ton

29 iul. 2025, 22:34 UTC

Câștiguri

IGO Expects Train 1 of Kwinana Refinery to Be Fully Impaired

29 iul. 2025, 22:34 UTC

Câștiguri

IGO Expects to Impair Kwinana Refinery Assets by A$70 Million-A$90 Million

29 iul. 2025, 22:34 UTC

Market Talk
Câștiguri

Mondelez Snack Demand Holding Up Better in Europe Than U.S. -- Market Talk

29 iul. 2025, 22:33 UTC

Câștiguri

IGO Had A$279.7 Million of Cash at End-June

29 iul. 2025, 22:33 UTC

Câștiguri

IGO 4Q Underlying Free Cash A$2.4 Million

29 iul. 2025, 22:33 UTC

Câștiguri

IGO FY Sales Revenue A$512.5 Million

29 iul. 2025, 22:33 UTC

Câștiguri

IGO 4Q Sales Revenue A$126.9 Million, Up 15% on 3Q

29 iul. 2025, 22:32 UTC

Câștiguri

IGO FY Nickel Production 17,173 Tons

29 iul. 2025, 22:32 UTC

Câștiguri

IGO 4Q Nickel Production 5,107 Tons, Up 22% on 3Q

29 iul. 2025, 22:32 UTC

Câștiguri

IGO 4Q Lithium Hydroxide Production 2,126 Tons, Up 36% on 3Q

29 iul. 2025, 22:31 UTC

Market Talk
Câștiguri

Global Equities Roundup: Market Talk

29 iul. 2025, 22:31 UTC

Market Talk
Câștiguri

Mondelez Sees Consumers Trading Down, Buying in Bulk -- Market Talk

29 iul. 2025, 22:31 UTC

Câștiguri

IGO 4Q Spodumene Cash Cost A$366/Ton, Up 7% on 3Q

29 iul. 2025, 22:31 UTC

Câștiguri

IGO FY Spodumene Production 1.48 Million Tons

29 iul. 2025, 22:30 UTC

Câștiguri

IGO 4Q Spodumene Production 340,000 Tons, Flat on 3Q

29 iul. 2025, 22:30 UTC

Câștiguri

IGO 4Q Underlying Ebitda A$62 Million

29 iul. 2025, 22:22 UTC

Câștiguri

Starbucks Abandons Mobile Order, Pickup-Only Stores -- WSJ

Comparație

Modificare preț

Innoviva Inc Așteptări

Obiectiv de preț

By TipRanks

117.53% sus

Prognoză pe 12 luni

Medie 40.33 USD  117.53%

Maxim 55 USD

Minim 26 USD

În baza a 3 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruInnoviva Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

3 ratings

3

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

18.57 / 18.75Suport & Rezistență

Termen scurt

Strong Bullish Evidence

Termen mediu

Weak Bullish Evidence

Termen lung

Neutral Evidence

Sentiment

By Acuity

148 / 375 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.